Compare CMTL & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMTL | IFRX |
|---|---|---|
| Founded | 1967 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.4M | 86.0M |
| IPO Year | N/A | 2017 |
| Metric | CMTL | IFRX |
|---|---|---|
| Price | $3.25 | $1.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $6.00 | ★ $8.50 |
| AVG Volume (30 Days) | 278.6K | ★ 7.7M |
| Earning Date | 01-12-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $499,528,000.00 | $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.15 | $1,075.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.19 | $0.71 |
| 52 Week High | $4.88 | $2.82 |
| Indicator | CMTL | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.52 | 42.21 |
| Support Level | $3.00 | $0.92 |
| Resistance Level | $3.32 | $1.28 |
| Average True Range (ATR) | 0.20 | 0.11 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 88.33 | 30.42 |
Comtech Telecommunications Corp is a provider of modern communications solution incorporated in USA. The company is engaged in designing, developing, producing and marketing products, systems, and services for communications solutions. It is engaged in two business segments, Satellite and Space Communications and Terrestrial and Wireless Networks. It's Space and satellite is USA based providers of modems and high-power amplifiers, a market leader in troposcatter technologies, and serves some of the world's defense contractors and allied foreign governments. Terrestrial and Wireless Networks segment is a provider of next generation 911 infrastructure and solutions for state and local governments and carriers. Majority of sales are generated from Satellite and Space Communications segment.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.